In new independent research reports released early this morning,
Capital Review released its latest key findings for all current
investors, traders, and shareholders of Zscaler, Inc. (NASDAQ:ZS),
Golden Star Resources, Ltd (NYSE:GSS), Flexion Therapeutics, Inc.
(NASDAQ:FLXN), SP Plus Corporation (NASDAQ:SP), Insys Therapeutics,
Inc. (NASDAQ:INSY), and OMNOVA Solutions Inc. (NYSE:OMN), including
updated fundamental summaries, consolidated fiscal reporting, and
fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available
to readers at the links below.
ZS DOWNLOAD: http://Capital-Review.com/register/?so=ZS
GSS DOWNLOAD: http://Capital-Review.com/register/?so=GSS FLXN
DOWNLOAD: http://Capital-Review.com/register/?so=FLXN SP DOWNLOAD:
http://Capital-Review.com/register/?so=SP INSY DOWNLOAD:
http://Capital-Review.com/register/?so=INSY OMN DOWNLOAD:
http://Capital-Review.com/register/?so=OMN
(You may have to copy and paste the link into your browser and
hit the [ENTER] key)
The new research reports from Capital Review,
available for free download at the links above, examine Zscaler,
Inc. (NASDAQ:ZS), Golden Star Resources, Ltd (NYSE:GSS), Flexion
Therapeutics, Inc. (NASDAQ:FLXN), SP Plus Corporation (NASDAQ:SP),
Insys Therapeutics, Inc. (NASDAQ:INSY), and OMNOVA Solutions Inc.
(NYSE:OMN) on a fundamental level and outlines the overall demand
for their products and services in addition to an in-depth review
of the business strategy, management discussion, and overall
direction going forward. Several excerpts from the recently
released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following
excerpts are not designed to be standalone summaries and as such,
important information may be missing from these samples. Please
download the entire research report, free of charge, to ensure you
are reading all relevant material information. Percentage
calculations are performed after rounding. All amounts in millions
(MM), except per share amounts.
-----------------------------------------
ZSCALER, INC. (ZS) REPORT OVERVIEW
Zscaler's Recent Financial Performance
For the three months ended January 31st, 2019 vs
January 31st, 2018, Zscaler reported revenue of $74.30MM vs
$44.98MM (up 65.20%) and analysts estimated basic earnings per
share -$0.03 vs -$0.29. For the twelve months ended July 31st, 2018
vs July 31st, 2017, Zscaler reported revenue of $190.17MM vs
$125.72MM (up 51.27%) and analysts estimated basic earnings per
share -$0.63 vs -$1.54. Analysts expect earnings to be released on
June 5th, 2019. The report will be for the fiscal period ending
April 30th, 2019. The reported EPS for the same quarter last year
was -$0.06. The estimated EPS forecast for the next fiscal year is
-$0.34 and is expected to report on September 4th, 2019.
To read the full Zscaler, Inc. (ZS) report, download it here:
http://Capital-Review.com/register/?so=ZS
-----------------------------------------
GOLDEN STAR RESOURCES, LTD (GSS) REPORT
OVERVIEW
Golden Star Resources' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Golden Star Resources reported revenue of
$57.34MM vs $81.85MM (down 29.94%) and analysts estimated basic
earnings per share -$0.10 vs $0.29. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Golden Star Resources
reported revenue of $273.02MM vs $315.50MM (down 13.46%) and
analysts estimated basic earnings per share -$0.21 vs $0.52.
Analysts expect earnings to be released on May 1st, 2019. The
report will be for the fiscal period ending March 31st, 2019.
Reported EPS for the same quarter last year was $0.00. The
estimated EPS forecast for the next fiscal year is $0.58 and is
expected to report on February 18th, 2020.
To read the full Golden Star Resources, Ltd (GSS) report,
download it here:
http://Capital-Review.com/register/?so=GSS
-----------------------------------------
FLEXION THERAPEUTICS, INC. (FLXN) REPORT
OVERVIEW
Flexion Therapeutics' Recent Financial
Performance
For the twelve months ended December 31st, 2018
vs December 31st, 2017, Flexion Therapeutics reported revenue of
$22.52MM vs $0.36MM (up 6,244.79%) and analysts estimated basic
earnings per share -$4.49 vs -$4.16. Analysts expect earnings to be
released on May 14th, 2019. The report will be for the fiscal
period ending March 31st, 2019. Reported EPS for the same quarter
last year was -$1.10. The estimated EPS forecast for the next
fiscal year is -$2.14 and is expected to report on February 27th,
2020.
To read the full Flexion Therapeutics, Inc. (FLXN) report,
download it here:
http://Capital-Review.com/register/?so=FLXN
-----------------------------------------
SP PLUS CORPORATION (SP) REPORT OVERVIEW
SP Plus' Recent Financial Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, SP Plus reported revenue of $377.30MM vs
$392.40MM (down 3.85%) and basic earnings per share $0.41 vs $0.35
(up 17.14%). For the twelve months ended December 31st, 2018 vs
December 31st, 2017, SP Plus reported revenue of $1,468.40MM vs
$1,590.50MM (down 7.68%) and analysts estimated basic earnings per
share $2.38 vs $1.86 (up 27.96%). Analysts expect earnings to be
released on May 1st, 2019. The report will be for the fiscal period
ending March 31st, 2019. The reported EPS for the same quarter last
year was $0.39. The estimated EPS forecast for the next fiscal year
is $2.75 and is expected to report on February 19th, 2020.
To read the full SP Plus Corporation (SP) report, download it
here:
http://Capital-Review.com/register/?so=SP
-----------------------------------------
INSYS THERAPEUTICS, INC. (INSY) REPORT
OVERVIEW
Insys Therapeutics' Recent Financial
Performance
For the three months ended December 31st, 2018
vs December 31st, 2017, Insys Therapeutics reported revenue of
$16.36MM vs $31.49MM (down 48.05%) and analysts estimated basic
earnings per share -$0.62 vs -$0.64. For the twelve months ended
December 31st, 2018 vs December 31st, 2017, Insys Therapeutics
reported revenue of $82.08MM vs $140.69MM (down 41.66%) and
analysts estimated basic earnings per share -$1.68 vs -$3.12.
Analysts expect earnings to be released on May 14th, 2019. The
report will be for the fiscal period ending March 31st, 2019. The
reported EPS for the same quarter last year was -$0.22. The
estimated EPS forecast for the next fiscal year is -$0.88 and is
expected to report on March 5th, 2020.
To read the full Insys Therapeutics, Inc. (INSY) report,
download it here:
http://Capital-Review.com/register/?so=INSY
-----------------------------------------
OMNOVA SOLUTIONS INC. (OMN) REPORT OVERVIEW
OMNOVA Solutions' Recent Financial
Performance
For the three months ended February 28th, 2019
vs February 28th, 2018, OMNOVA Solutions reported revenue of
$168.90MM vs $178.70MM (down 5.48%) and analysts estimated basic
earnings per share -$0.10 vs $0.16. For the twelve months ended
November 30th, 2018 vs November 30th, 2017, OMNOVA Solutions
reported revenue of $769.80MM vs $783.10MM (down 1.70%) and
analysts estimated basic earnings per share $0.46 vs -$1.98.
Analysts expect earnings to be released on June 27th, 2019. The
report will be for the fiscal period ending May 31st, 2019. The
reported EPS for the same quarter last year was $0.20. The
estimated EPS forecast for the next fiscal year is $0.75 and is
expected to report on January 30th, 2020.
To read the full OMNOVA Solutions Inc. (OMN) report, download it
here:
http://Capital-Review.com/register/?so=OMN
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized
publisher of financial analysis, research reports, and exclusive
market reporting. Institutional investors, registered brokers,
professional traders, and personal investment advisers rely on
Capital Review to quantify public company valuations, discover
opportunity across asset classes, stay informed about market-moving
events, and read exclusive analysis of important material
developments. With 14 offices worldwide, Capital Review staffs and
manages certified and registered financial professionals, including
Chartered Financial Analyst® (CFA®) designation holders and FINRA®
BrokerCheck® certified individuals with current and valid CRD®
number designations, to enable continuous coverage of topics
relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are
registered analysts, brokers, and/or financial advisers
("Registered Members") working within Equity Research, Media, and
Compliance departments. Capital Review's roster includes qualified
CFA® charterholders, licensed securities attorneys, and registered
FINRA® members holding duly issued CRD® numbers. Current licensed
status of several Registered Members at Capital Review have been
independently verified by an outside audit firm, including policy
and audit records duly executed by Registered Members. Complaints,
concerns, questions, or inquiries regarding this release should be
directed to Capital Review's Compliance department by Phone, at +1
(410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or
solicitation to buy, hold, or sell any security. Capital Review,
Capital Review members, and/or Capital Review affiliates are not
responsible for any gains or losses that result from the opinions
expressed. Capital Review makes no representations as to the
completeness, accuracy, or timeliness of the material provided and
all materials are subject to change without notice. Capital Review
has not been compensated for the publication of this press release
by any of the above mentioned companies. Capital Review is not a
financial advisory firm, investment adviser, or broker-dealer, and
does not undertake any activities that would require such
registration. For our full disclaimer, disclosure, and terms of
service please visit our website.
Media Contact: Morena Zambada, Media Department
Office: +1 (410) 280-7496 E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For
republishing permissions, please contact a partner network manager
at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered
trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks
owned by Financial Industry Regulatory Authority, Inc.
OMNOVA Solutions (NYSE:OMN)
Historical Stock Chart
Von Okt 2024 bis Nov 2024
OMNOVA Solutions (NYSE:OMN)
Historical Stock Chart
Von Nov 2023 bis Nov 2024